BACKGROUND: Long-acting muscarinic antagonist (LAMA)/long-acting b 2 -agonist (LABA)
However, factors that have become increasingly evident are the importance of the inhaler device, patient preference, and adherence. 11, 12 Until now, the obtainable combinations have been available as dry powder inhalers (DPIs) or as a soft mist inhaler. 7 Metered dose inhalers (MDIs) remain the most common inhalers used to deliver short-acting bronchodilators, 1 so many patients may begin inhaled therapy using this device and are familiar with its use.
GFF MDI is an FDC of the LAMA glycopyrrolate (GP) and the LABA formoterol fumarate (FF) in a pressurized MDI. It is formulated using Co-Suspension Delivery Technology developed to overcome the technical difficulties of MDI formulation (eg, sedimentation, creaming, aggregation with particle growth, poor aerosolization properties 13 ) using hydrofluoroalkane (HFA) propellants. Drug particles are suspended in the HFA propellant by the use of spray-dried porous particles of distearoyl-phosphatidylcholine. These porous particles form strong associations with the drug particles and minimize drug-drug interactions. These Co-Suspension Delivery Technology formulations have demonstrated excellent stability and dose uniformity, even in the nanogram dose range, with one, two, or three drugs formulated in the same inhaler. [14] [15] [16] [17] GP and FF have well-established clinical profiles in COPD and are approved both as monotherapies and combinations. 6, [18] [19] [20] [21] Efficacy and safety data from nine double-blind studies, which evaluated GP MDI at doses of 0.6 to 144 mg and FF MDI at doses of 2.4 to 19.2 mg, supported selection of GP MDI, FF MDI, and GFF MDI doses for phase III evaluation. [22] [23] [24] [25] [26] [27] The Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-1) (NCT01854645) and the Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-2) (NCT01854658) phase III studies investigated the efficacy and safety of GFF MDI 18/9.6 mg bid vs monocomponent and placebo MDIs.
PINNACLE-1 included open-label tiotropium bromide
18 mg DPI (daily, Spiriva HandiHaler) as active comparator (European registration requirement). Lung function, symptom control, and health-related quality of life (HRQoL) end points used to support US registration are presented. e-Appendix 1 presents the list of principal investigators in PINNACLE-1 and PINNACLE-2.
Methods
Study Design and Treatment Figure 1 shows the patient flow for both studies. PINNACLE-1 was conducted across 160 sites (United States, Australia, and New Zealand), and PINNACLE-2 encompassed 140 sites (United States).
The full Methods description is shown in e-Appendix 2. Briefly, after a 4-week screening period, patients were randomized 7:6:6:6:3 to GFF MDI 18/9.6 mg (also described as and equivalent to glycopyrronium/ formoterol fumarate dihydrate 14. European Respiratory Society criteria) 28 and were current/ex-smokers ($ 10 pack-years). Moderate-to-very severe COPD was defined as postbronchodilator FEV 1 /FVC ratio < 0.70 and FEV 1 < 80% predicted. Patients with FEV 1 < 30% predicted were required to have postbronchodilator FEV 1 $ 750 mL. Dyspnea and disease burden were assessed (visit 2) using the Modified Medical Research Council (MMRC) Dyspnea Scale 29 and the COPD Assessment Test (CAT), 30 respectively; these assessments were not used as entry criteria, as there was no requirement for patients to be symptomatic. Laboratory tests and clinical examinations were performed prior to enrollment to assess eligibility.
The main exclusion criteria were significant diseases other than COPD; pregnant/lactating women; lung volume reduction surgery, including lobectomy or bronchoscopic lung volume reduction # 1 year prior to visit 1; hospitalization due to COPD within 3 months or during screening; smoking status change during screening; long-term oxygen therapy required > 12 hours/d; and inability to produce acceptable/reproducible spirometry results.
Patients could withdraw at any point, and trial investigators could withdraw patients if they met early termination criteria including more than two moderate COPD exacerbations (requiring systemic steroids/antibiotics), one severe COPD exacerbation (requiring hospitalization), or the use of prohibited medications.
Assessments
At each visit, investigators confirmed whether patients had refrained from using COPD medications (including study medications) in the preceding 6 hours. Spirometry was performed in accordance with ATS criteria 31 before administration of study medication at all visits and after administration at all visits except week 4 (visit 6) and week 16 (visit 9) (Fig 2) . HRQoL was assessed using St. George's Respiratory Questionnaire (SGRQ) 32 on day 1 and at weeks 12, 16, 20, and 24.
Daily symptoms, including rescue albuterol use, were recorded in electronic diaries and used to calculate a daily total symptom score (TSS), which was the sum of numeric scores assigned to patient responses for individual symptom questions (cough, shortness of breath, sputum volume, nighttime awakenings, and rescue albuterol use). Adverse events (AEs) were recorded.
A subset of patients from both studies participated in a 12-hour pulmonary function test (PFT) substudy on day 1 and at week 12. In PINNACLE-2, a subset of patients participated in a 24-hour Holter substudy at screening (visit 3) and week 4.
The primary objective of PINNACLE-1 and PINNACLE-2 was to confirm the efficacy of GFF MDI vs monocomponent and placebo MDIs. The primary and secondary end points, and type I error control, varied according to regional regulatory registration requirements. Results are presented here using the US approach (e-Appendix 3).
Change from baseline in morning predose trough FEV 1 at week 24 was the primary efficacy end point and over 24 weeks (using all assessments) was a secondary end point. Other secondary end points included peak change from baseline in FEV 1 within 2 hours journal.publications.chestnet.org postdose at week 24, time to onset of action (defined as the first time point at which the difference from placebo MDI for change from baseline in FEV 1 was statistically significant) on day 1, change from baseline in SGRQ total score at week 24, and change from baseline in average daily rescue albuterol use over 24 weeks. Other end points included mean daily TSS and rescue albuterol (daytime and nighttime) use.
The PFT substudy evaluated the effect of treatment on lung function parameters over 12 hours. The primary end point for this substudy was 0-to 12-hour postdose area under the FEV 1 curve (FEV 1 AUC 0-12 ) at week 12. The 24-hour Holter substudy evaluated the cardiac safety of study treatments. The primary end point was a change from baseline in 24-hour averaged mean heart rate (HR) at week 4.
Statistical Analysis
The primary analyses were conducted using the intent-to-treat (ITT) population. The safety population was similar to the ITT population but was analyzed according to treatment received. All efficacy end points were relative to predose baselines obtained at or prior to day 1.
For PINNACLE-1 and PINNACLE-2, 2,054 and 1,614 patients, respectively, were required to achieve approximately 90% power across all five key comparisons for change from baseline in morning predose trough FEV 1 at week 24 with type I error, controlled at 5% (two-sided) using sequential testing. A repeated-measures linear model was used to analyze primary end points and included visit, treatment, treatment by visit, and baseline covariates for FEV 1 , bronchodilator reversibility, smoking status, and ICS use. The covariance matrix was unstructured. Similar models were used for secondary end points. A combination of sequential testing and the Hochberg procedure was used to control multiplicity for secondary end points. P values < .05, but not included in the type I error procedures or not significant due to these procedures, are referred to as nominally significant.
Results

Patients
Overall, 2,103 patients were randomized in PINNACLE-1 and 1,615 in PINNACLE-2 (Fig 1) . Across both studies, 718 and 585 patients, respectively, participated in the PFT substudy, and 585 patients participated in the PINNACLE-2 Holter substudy.
Baseline characteristics in both studies were similar across treatment arms (Table 1) . Overall, of 3,699 patients with evaluable data, 7.2%, 41.6%, 5.1%, and 45.6% of patients were in Global Initiative for Chronic Obstructive Lung Disease (GOLD) categories A, B, C, and D, respectively. Overall, 87.2% of patients were symptomatic as defined by a CAT score $ 10, and 57.1% had an MMRC grade $ 2.0.
Efficacy
In both studies, GFF MDI, GP MDI, and FF MDI showed significant improvements vs placebo MDI in change from baseline in morning predose trough FEV 1 at week 24 (all P < .0001; data not shown for GP MDI and FF MDI vs placebo MDI) ( Table 2) . GFF MDI showed significant differences vs placebo MDI of 150 mL and 103 mL in PINNACLE-1 and PINNACLE-2, respectively (all P < .0001). In PINNACLE-1, GFF MDI showed significant differences of 59 mL and 64 mL vs GP MDI and FF MDI, respectively (all P < .0001). In PINNACLE-2, GFF MDI showed significant differences of 54 mL (P ¼ .0003) and 56 mL (P ¼ .0002) vs GP MDI and FF MDI, respectively. The change from baseline in morning predose trough FEV 1 over 24 weeks was similar but with slightly larger estimated differences vs placebo MDI (Fig 3, Table 2 ). A prospective subgroup analysis of the pooled ITT population showed that the benefits of GFF MDI on change from baseline in morning predose trough FEV 1 over 24 weeks were consistent regardless of concomitant ICS use (e- Table 1 ).
For peak change from baseline in FEV 1 within 2 hours postdose at week 24 (Table 2) , GFF MDI showed significant differences vs placebo and monocomponent MDIs in both PINNACLE-1 and PINNACLE-2 (all P < .0001). The change from baseline in peak FEV 1 within 2 hours postdose over 24 weeks was similar (Fig 4) . For onset of action on day 1 (Table 2) , GFF MDI showed a significant difference from placebo MDI at 5 min, which was the first time point assessed in both studies, with respective differences of 187 mL and 186 mL (all P < .0001).
In PINNACLE-1 only, GFF MDI showed significant differences in SGRQ total score at week 24 vs placebo (-2.52) and GP MDIs (-2.33) ( Table 3 ). GFF MDI-treated patients were more likely to achieve the minimum clinically important difference of 4 units in SGRQ total score vs GP MDI and placebo MDI in PINNACLE-1 (all P < .05). In PINNACLE-1 and PINNACLE-2, GFF MDI showed a significant reduction in rescue albuterol use over 24 weeks vs placebo MDI (-1.08 and -1.04 puffs/d, respectively) ( Table 3 ). In PINNACLE-2, a significant reduction vs GP MDI (-0.57) was seen, with nominal significance vs FF MDI (-0.29). In both studies, there was a nominally significant difference in change from baseline in mean daily TSS over 24 weeks for GFF MDI vs placebo MDI (Table 3) . GFF MDI showed a nominally significant difference in change from baseline vs GP MDI in both studies but not vs FF MDI.
In the 12-hour PFT substudy of PINNACLE-1, GFF MDI showed significant improvements in FEV 1 AUC 0-12 at week 12 vs placebo MDI, GP MDI, and FF MDI of 237 mL (P < .0001), 102 mL (P < .0001), and 56 mL (P ¼ .0196), respectively. Similarly in the PINNACLE-2 PFT substudy, GFF MDI showed significant improvements in FEV 1 AUC 0-12 at week 12 vs placebo MDI, GP MDI, and FF MDI of 209 mL (P < .0001), 98 mL (P < .0001), and 67 mL, respectively (P ¼ .0056) (e -Fig 1) . GFF MDI significantly improved evening 12-hour postdose trough FEV 1 by 144 mL in PINNACLE-1 and by 158 mL in PINNACLE-2 vs placebo MDI (both P < .0001), with significant improvements vs GP MDI (61 mL; P ¼ .0196) and FF MDI (65 mL; P ¼ .0145) in PINNACLE-2.
Safety and Tolerability
In PINNACLE-1 and PINNACLE-2, 58.8% to 62.9% and 52.5% to 56.1% of patients, respectively, reported one or more AEs (Table 4) . Across both studies, the most common AEs included nasopharyngitis, cough, upper respiratory tract infection, sinusitis, and dyspnea, which occurred with a frequency similar to that with placebo MDI in each active treatment group.
Rates of serious AEs were similar for active treatment and placebo MDI. Rates of AE-related discontinuations were similar across treatment groups in both studies and were slightly lower in the FF MDI and open-label tiotropium arms vs the other treatment arms in PINNACLE-1. The incidence of cardiovascular events of special interest was low and similar across treatment groups in both studies.
Few deaths were observed, and all were considered not related to the study drug. No important trends were observed in clinical laboratory results, vital signs, or electrocardiograms.
24-Hour Holter Substudy
Change from baseline in 24-hour mean HR at week 4 was similar across treatment groups, with the CI excluding clinically relevant differences. No important differences were observed for other Holter substudy end points at week 4, including changes from baseline in daytime and nighttime mean HRs, maximum and minimum 24-hour HRs, and frequency of isolated ventricular events, supraventricular events, and atrial fibrillation (e- Table 2 ).
Discussion
The PINNACLE-1 and PINNACLE-2 results demonstrated that GFF MDI, formulated with the novel CoSuspension Delivery Technology, conferred greater benefits vs placebo and monocomponent MDIs in journal.publications.chestnet.org In both studies, GFF MDI provided clinical benefit in morning predose trough FEV 1 vs monocomponent and placebo MDIs at week 24 and also over 24 weeks. These improvements in trough FEV 1 vs placebo were of a magnitude anticipated from phase III studies reported for LAMA/LABA FDCs delivered by DPI or soft mist inhaler. 10 Notably, peak change from baseline in FEV 1 within 2 hours postdose showed differences for GFF MDI vs GP MDI at week 24 > 100 mL in both studies (PINNACLE-1, 133 mL; PINNACLE-2, 126 mL), with improvements vs FF MDI exceeding 80 mL. 33 The available LAMA/LABA FDCs all improve lung function, dyspnea, and quality of life vs placebo and monocomponents, 10 and there may now be an increased focus on these agents since a LAMA/LABA FDC has been shown to decrease the incidence of moderate or severe exacerbations compared with an ICS/LABA FDC. 34 However, the absence of head-to-head trials makes it difficult to compare the various LAMA/LABA combinations. PINNACLE-1 and PINNACLE-2 contrast with other LAMA/LABA FDC studies because enrollment required a diagnosis of COPD defined using spirometry but did not require patients to be symptomatic; 12.3% of patients had CAT scores < 10, and 42.7% had an MMRC grade < 2.0. Phase III studies of other LAMA/LABA FDCs have prespecified symptomatic COPD in the inclusion criteria. 5, 8, 35, 36 Further investigations are required to determine the characteristics of patients with COPD who would benefit most from LAMA/LABA FDCs. 37 Currently, GOLD recommends LAMA/LABA combination therapy as an alternative option for patients remaining symptomatic on a single agent.
1
In both PINNACLE-1 and PINNACLE-2 studies, patients in the placebo arm used rescue medication more often than patients in the other arms and withdrew from the study in higher proportions. In this context, GFF MDI led to a statistically significant reduction in rescue medication use over 24 weeks vs placebo MDI and vs GP MDI/FF MDI in PINNACLE-2; this was within the range demonstrated for other LAMA/LABA FDCs. 2, 3, 8, 36, 38 HRQoL (by SGRQ results) showed a statistically significant but modest improvement with GFF MDI vs placebo MDI (and GP MDI) in PINNACLE-1 only. 39 The open-label nature of tiotropium treatment may also have affected the results for some end points.
In conclusion, the PINNACLE-1 and PINNACLE-2 results demonstrate the efficacy and safety of GFF MDI 18/9.6 mg, a LAMA/LABA Co-Suspension Delivery Technology FDC MDI given bid in patients with moderate-to-very severe COPD.
